Novel antifungal agents, targets or therapeutic strategies for the treatment of invasive fungal diseases: a review of the literature (2005-2009)

Revista Iberoamericana de Micologia

Volumn 26, Issue 1, 2009, Pages 15-22

  Espinel Ingroff, Ana ^a  

^a VIRGINIA COMMONWEALTH UNIVERSITY MEDICAL CENTER   (United States)

Author keywords

Antifungal concentrations monitoring; Echinocandins; Genetic studies; New antifungal activity targets; New antifungal therapy strategies; Novel antifungal agents

Indexed keywords

2 AMINO 4 METHYLENECYCLOPENTANECARBOXYLIC ACID; 2 AMINOCYCLOPENTANECARBOXYLIC ACID; 4 [2 [2 (2,5 DIFLUOROPHENYL) 2 HYDROXY 1 METHYL 3 (1H 1,2,4 TRIAZOL 1 YL)PROPYL] 4 THIAZOLYL]BENZONITRILE; AMBRUTICIN; AMIDINE; AMPHOTERICIN B; AMPHOTERICIN B LIPID COMPLEX; ANTIFUNGAL AGENT; BENZIMIDAZOLE DERIVATIVE; BETA 1,6 GLUCAN; CASPOFUNGIN; CHITIN SYNTHASE INHIBITOR; ECHINOCANDIN; ENZYME INHIBITOR; FATTY ACID; FLUCONAZOLE; FLUCYTOSINE; ICOFUNGIPEN; ITRACONAZOLE; MEVINOLIN; MICAFUNGIN; MYCOGRAB; PEPTIDE DERIVATIVE; PHOSPHOLIPASE INHIBITOR; POLYENE; POSACONAZOLE; SPK 843; T 2307; TRIAZOLE DERIVATIVE; UNCLASSIFIED DRUG; UNINDEXED DRUG; VORICONAZOLE;

ANTIFUNGAL ACTIVITY; ASPERGILLOSIS; ASPERGILLUS FUMIGATUS; BIOFILM; CANDIDA ALBICANS; CANDIDA ENDOCARDITIS; CANDIDIASIS; CLINICAL PROTOCOL; CLINICAL TRIAL; COCCIDIOIDOMYCOSIS; CRYPTOCOCCOSIS; CRYPTOCOCCUS NEOFORMANS; DISEASE MODEL; DRUG EFFICACY; DRUG MECHANISM; DRUG MONITORING; DRUG POTENTIATION; DRUG TARGETING; FUNGAL VIRULENCE; FUNGUS GROWTH; GENE IDENTIFICATION; HISTOPLASMOSIS; HUMAN; IN VITRO STUDY; IN VIVO STUDY; INVASIVE CANDIDIASIS; LUNG ASPERGILLOSIS; MINIMUM INHIBITORY CONCENTRATION; MUCORMYCOSIS; MYCOSIS; NONHUMAN; PHARMACODYNAMICS; REVIEW;

ANIMALS; ANTIFUNGAL AGENTS; BIOFILMS; CANDIDA ALBICANS; CLINICAL TRIALS AS TOPIC; CRYPTOCOCCUS NEOFORMANS; DRUG DELIVERY SYSTEMS; DRUG DISCOVERY; DRUG EVALUATION, PRECLINICAL; DRUG MONITORING; DRUG SYNERGISM; DRUGS, INVESTIGATIONAL; ENZYME INHIBITORS; FATTY ACIDS; FUNGAL PROTEINS; HUMANS; MYCOSES; PEPTIDES;

ANIMALIA;

EID: 67650723105     PISSN: 11301406     EISSN: None     Source Type: Journal    
DOI: 10.1016/S1130-1406(09)70004-X     Document Type: Review

References (114)

1. Aerts A.M., Francois I.E., Meert E.M., Li Q.T., Cammue B.P., and Thevissen K. The antifungal activity of RsAFP2, a plant defensin from raphanus sativus, involves the induction of reactive oxygen species in Candida albicans. J Mol Microbiol Biotechnol 13 (2007) 243-247
2. Andes D.R., Diekema D.J., Pfaller M.A., Marchillo K., and Bohrmueller J. In vivo pharmacodynamic target investigation for micafungin against Candida albicans and C. glabrata in a neutropenic murine candidiasis model. Antimicrob Agents Chemother 52 (2008) 3497-3503
3. Andes D., Pascual A., and Marchetti O. Antifungal therapeutic drug monitoring: established and emerging indications. Antimicrob Agents Chemother 53 (2009) 24-34
4. Antimicrobial Agents Chemotherapy. New antimicrobial agents approved by the U.S. food and drug administration in 2004 and new indications for previously approved agents. Antimicrob Agents Chemother 49 (2005) 2151
5. Antimicrobial Agents Chemotherapy. New antimicrobial agents approved by the U.S. food and drug administration in 2005 and new indications for previously approved agents. Antimicrob Agents Chemother 50 (2006) 1912
6. Antimicrobial Agents Chemotherapy. New antimicrobial agents approved by the U.S. food and drug administration in 2006 and new indications for previously approved agents. Antimicrob Agents Chemother 51 (2007) 2649
7. Arendrup M.C., Fuursted K., Gahrn-Hansen B., Jensen I.M., Knudsen J.D., Lundgren B., Schonheyder H.C., and Tvede M. Seminational surveillance of fungemia in Denmark: notably high rates of fungemia and numbers of isolates with reduced azole susceptibility. J Clin Microbiol 43 (2005) 4434-4440
8. Arendrup M.C., Perkhofer S., Howard S.J., Garcia-Effron G., Vishukumar A., Perlin D., and Lass-Florl C. Establishing in vitro-in vivo correlations for Aspergillus fumigatus: the challenge of azoles versus echinocandins. Antimicrob Agents Chemother 52 (2008) 3504-3511
9. Benincasa M., Scocchi M., Pacor S., Tossi A., Nobili D., Basaglia G., Busetti M., and Gennaro R. Fungicidal activity of five cathelicidin peptides against clinically isolated yeasts. J Antimicrob Chemother 58 (2006) 950-959
10. Cabras T., Longhi R., Secundo F., Nocca G., Conti S., Polonelli L., Fanali C., Inzitari R., Petruzzelli R., Messana I., Castagnola M., and Vitali A. Structural and functional characterization of the porcine proline-rich antifungal peptide SP-B isolated from salivary gland granules. J Pept Sci 14 (2008) 251-260
11. Carballeira N.M., O'Neill R., and Parang K. Synthesis and antifungal properties of alphamethoxy and alpha-hydroxyl substituted 4-thiatetradecanoic acids. Chem Phys Lipids 150 (2007) 82-88
12. Cao Y., Dai B., Wang Y., Huang S., Xu Y., Gao P., Zhu Z., and Jiang Y. In vitro activity of baicalein against Candida albicans biofilms. Int J Antimicrob Agents 32 (2008) 73-77
13. Casadevall A. The third age of antimicrobial therapy. Clin Infect Dis 42 (2006) 1414-1416
14. Cateau E., Rodier M.H., and Imbert C. In vitro efficacies of caspofungin or micafungin catheter lock solutions on Candida albicans biofilm growth. J Antimicrob Chemother 62 (2008) 153-155
15. Chamilos G., Lewis R.E., and Kontoyiannis D.P. Inhibition of Candida parapsilosis mitochondrial respiratory pathways enhances susceptibility to caspofungin. Antimicrob Agents Chemother 50 (2006) 744-747
16. Chamilos G., Lewis R.E., and Kontoyiannis D.P. Lovastatin has significant activity against zygomycetes and interacts synergistically with voriconazole. Antimicrob Agents Chemother 50 (2006) 96-103
17. Chayakulkeeree M., Rude T.H., Toffaletti D.L., and Perfect J.R. Fatty acid synthesis is essential for survival of Cryptoccus neoformans and a potential fungicidal target. Antimicrob Agents Chemother 51 (2007) 3537-3545
18. Chen L., Shen Z., and Wu J. Expression, purification and in vitro antifungal activity of acidic mammalian chitinase against Candida albicans, Aspergillus fumigatus and Trichophyton rubrum strains. Clin Exp Dermatol 34 (2009) 55-60
19. Chiang L.Y., Ejzykowicz D.E., Tian Z.Q., Katz L., and Filler S.G. Efficacy of ambruticin analogs in a murine model of invasive pulmonary aspergillosis. Antimicrob Agents Chemother 50 (2006) 3464-3466
20. Clement M., Tremblay J., Lange M., Thibodeau J., and Belhumeur P. Whey-derived free fatty acids suppress the germination of Candida albicans in vitro. FEMS Yeast Res 7 (2007) 276-285
21. Dalleau S., Cateau E., Berges T., Berjeaud J.M., and Imbert C. In vitro activity of terpenes against Candida biofilms. Int J Antimicrob Agents 31 (2008) 572-576
22. D'Auria F.D., Tecca M., Strippoli V., Salvatore G., Battinelli L., and Mazzanti G. Antifungal activity of Lavandula angustifolia essential oil against Candida albicans yeast and mycelial form. Med Mycol 43 (2005) 391-396
23. Dennis C.G., Greco W.R., Brun Y., Youn R., Slocum H.K., Bernacki R.J., Lewis R., Wiederhold N., Holland S.M., Petraitiene R., Walsh T.J., and Segal B.H. Effect of amphotericin B and micafungin combination on survival, histopathology, and fungal burden in experimental aspergillosis in the p47phox-/-mouse model of chronic granulomatous disease. Antimicrob Agents Chemother 50 (2006) 422-427
24. Enoch D.A., Ludlam H.A., and Brown N.M. Invasive fungal infections: a review of epidemiology and management options. J Med Microbiol 55 (2006) 809-818
25. Espinel-Ingroff A. Mechanisms of resistance to antifungal agents: yeasts and filamentous fungi. Rev Iberoam Micol 25 (2008) 101-106
26. Fitzgerald-Hughes D.H., Coleman D.C., and O'Connell B.C. Differentially expressed proteinsin derivatives of Candida albicans displaying a stable histatin 3-resistant phenotype. Antimicrob Agents Chemother 51 (2007) 2793-2800
27. Foldvari M., Jaafari M.R., Radhi J., and Segal D. Efficacy of the antiadhesin octyl O-(2- acetamido-2-deoxy-β-D-galactopyranosyl)-(1-4)-2-O-propyl-β-Dgalactopyranoside (fimbrigal-P) in a rat oral candidiasis model. Antimicrob Agents Chemother 49 (2008) 2887-2894
28. Freifeld A., Arnold S., Ooi W., Chen F., Meyer T., Wheat L.J., Smedema M., Lemonte A., and Connolly P. Relationship of blood level and susceptibility in voriconazole treatment of histoplasmosis. Antimicrob Agents Chemother 51 (2007) 2656-2657
29. Garcia-Effron G., Kontoyiannis D.P., Lewis R.E., and Perlin D.S. Caspofungin-resistant Candida tropicalis strains causing breakthrough fungemia in patients at high risk for hematologic malignancies. Antimicrob Agents Chemother 52 (2005) 4181-4183
30. Garcia-Effron G., Park S., and Perlin D.S. Correlating echinocandin MIC and kinetic inhibition of fks1 mutant glucan synthases for Candida albicans: implications for interpretive breakpoints. Antimicrob Agents Chemother 53 (2009) 112-122
31. Gordon-Thomson C, Kumari A, Tomkins L, Holford P, Djordjevic JT, Wright LC, Sorrell TC, Moore GP. Chitotriosidase and gene therapy for fungal infections. Cell Mol Life Sci. 2009. [In press].
32. Guinea J., Pelaez T., Recio S., Torres-Narbona M., and Bouza E. In vitro antifungal activities of isavuconazole (BAL-4815), voriconazole, and fluconazole against 1,007 isolates of zygomycete, Candida, Aspergillus, Fusarium, and Scedosporium species. Antimicrob Agents Chemother 52 (2008) 1396-1400
33. Gumbo T., Drusano G.L., Liu W., Kulawy R.W., Fregeau C., Hsu V., and Louie A. Once-weekly micafungin therapy is as effective as daily therapy for disseminated candidiasis in mice with persistent neutropenia. Antimicrob Agents Chemother 51 (2007) 968-974
34. Gumbo T., Hiemenz J., Ma L., Keirns J.J., Buell D.N., and Drusano G.L. Population pharmacokinetics of micafungin in adult patients. Diagn Microbiol Infect Dis 60 (2008) 329-331
35. Hachem R., Bahna P., Hanna H., Stephens L.C., and Raad I. EDTA as an adjunct antifungal agent for invasive pulmonary aspergillosis in a rodent model. Antimicrob Agents Chemother 50 (2006) 1823-1827
36. Hasenoehrl A., Galic T., Ergovic G., Marsic N., Skerlev M., Mittendorf J., Geschke U., Schmidt A., and Schoenfeld W. In vitro activity and in vivo efficacy of icofungipen (PLD-118), a novel oral antifungal agent, against the pathogenic yeast Candida albicans. Antimicrob Agents Chemother 50 (2006) 3011-3018
37. Henry C.I., Mouya I., and Latge J.P. Testing the efficacy of RNA interference constructs in Aspergillus fumigatus. Curr Genet 51 (2007) 277-284
38. Hiemenz J., Cagnoni P., Simpson D., Devine S., Chao N., Keirns J., Lau W., Facklam D., and Buell D. Pharmacokinetic and maximum tolerated dose study of micafungin in combination with fluconazole versus fluconazole alone for prophylaxis of fungal infections in adult patients undergoing a bone marrow or peripheral stem cell transplant. Antimicrob Agents Chemother 49 (2005) 1331-1336
39. Hodgetts S., Nooney L., Al-Akeel R., Curry A., Awad S., Matthews R., and Burnie J. Efungumab and caspofungin: pre-clinical data supporting synergy. J Antimicrob Chemother 61 (2008) 1132-1139
40. Hope W.W., Seibel N.L., Schwartz C.L., Arrieta A., Flynn P., Shad A., Albano E., Keirns J.J., Buell D.N., Gumbo T., Drusano G.L., and Walsh T.J. Population pharmacokinetics of micafungin in pediatric patients and implications for antifunghal dosing. Antimicrob Agents Chemother 51 (2007) 3714-3719
41. Hope W.W., Warn P.A., Sharp A., Howard S., Kasai M., Louie A., Walsh T.J., Drusano G.L., and Denning D.W. Derivation of an in vitro drug exposure breakpoint for flucytosine against Candida albicans and the impact of the MIC growth rate, and resistance genotype on the antifungal effect. Antimicrob Agents Chemother 50 (2006) 3680-3688
42. Jang W.S., Li X.S., Sun J.N., and Edgerton M. The P-113 fragment of histatin 5 requires a specific peptide sequence for intracellular translocation in Candida albicans, which is independent of cell wall binding. Antimicrob Agents Chemother 52 (2008) 497-504
43. Jiang B., Xu D., Allocco J., Parish C., Davison J., Veillette K., Sillaots S., Hu W., Rodriguez- Suarez R., Trosok S., Zhang L., Li Y., Rahkhoodaee F., Ransom T., Martel N., Wang H., Gauvin D., Wiltsie J., Wisniewski D., Salowe S., Kahn J.N., Hsu M.J., Giacobbe R., Abruzzo G., Flattery A., Gill C., Youngman P., Wilson K., Bills G., Platas G., Pelaez F., Diez M.T., Kauffman S., Becker J., Harris G., Liberator P., and Roemer T. PAP inhibitor with in vivo efficacy identified by Candida albicans genetic profiling of natural products. Chem Biol 15 (2008) 363-374
44. Jung H.J., Sung W.S., Yeo S.H., Kim H.S., Lee I.S., Woo E.R., and Lee D.G. Antifungal effect of amentoflavone derived from Selaginella tamariscina. Arch Pharm Res 29 (2006) 746-751
45. Kakeya H., Miyazaki Y., Senda H., Kobayashi T., Seki M., Izumikawa K., Yanagihara K., Yamamoto Y., Tashiro T., and Kohno S. Efficacy of SPK-843, a novel polyene antifungal, in comparison with amphotericin B, liposomal amphotericin B, and micafungin against murine pulmonary aspergillosis. Antimicrob Agents Chemother 52 (2008) 1868-1870
46. Kanafani Z.A., and Perfect J.R. Resistance to antifungal agents: mechanisms and clinical impact. Clin Infect Dis 46 (2006) 120-128
47. Kang T.H., Hwang E.I., Yun B.S., Park K.D., Kwon B.M., Shin C.S., and Kim S.U. Inhibition of chitin synthases and antifungal activities by 2'-benzoyloxycinnamaldehyde from Pleuropterus cillinervis and its derivatives. Biol Pharm Bull 30 (2007) 598-602
48. Kang T.H., Hwang E.I., Yun B.S., Shin C.S., and Kim S.U. Chitin synthase 2 inhibitory activity of O-methyl pisiferic acid and 8,20-dihydroxy-9 (11), 13-abietadien-12-one, isolated from Chamaecyparis pisifera. Biol Pharm Bull 31 (2008) 755-759
49. Keirns J., Sawamoto T., Holum M., Buell D., Wisemandle W., and Alak A. Steady-state pharmacokinetics of micafungin and voriconazole after separate and concomitant dosing in healthy adults. Antimicrob Agents Chemother 51 (2007) 787-790
50. Kitamura A., Someya K., Hata M., Nakajima R., and Takemura M. Discovery of a smallmolecule inhibitor of β-1,6-glucan synthesis. Antimicrob Agents Chemother 53 (2009) 670-677
51. Krishnakumari V., Rangaraj N., and Nagaraj R. Antifungal activities of human beta-defensins HBD-1 to HBD-3 and their C-terminal analogs Phd1 to Phd3. Antimicrob Agents Chemother 53 (2009) 256-260
52. Kunze B., Steinmetz H., Hofle G., Huss M., Wieczorek H., Reichenbach H., and Cruentaren. a new antifungal salicylate-type macrolide from Byssovorax cruenta (myxobacteria) with inhibitory effect on mitochondrial ATPase activity. Fermentation and biological properties. J Antibiot (Tokyo) 59 (2006) 664-668
53. Larsen R.A., Pappas P.G., Perfect J., Aberg J.A., Casadevall A., Cloud G.A., James R., Filler S., and Dismukes W.E. Phase I evaluation of the safety and pharmacokinetics of murine-derived anticryptococcal antibody 18B7 in subjects with treated cryptococcal meningitis. Antimicrob Agents Chemother 49 (2005) 952-958
54. Lass-Florl C., Griff K., Mayr A., Petzer A., Gastl G., Bonatti H., Freund M., Kropshofer G., Dierich M.P., and Nachbaur D. Epidemiology and outcome of infections due to Aspergillus terreus: 10-year single centre experience. Brit J Haematol 131 (2005) 201-207
55. Leung E.H., Wong J.H., and Ng T.B. Concurrent purification of two defense proteins from French bean seeds: a defensin-like antifungal peptide and a hemagglutinin. J Pept Sci 14 (2008) 349-353
56. Li X.C., Jacob M.R., Khan S.I., Ashfaq M.K., Babu K.S., Agarwal A.K., ElSohly H.N., Manly S.P., and Clark A.M. Potent in vitro antifungal activities of naturally occurring acetylenic acids. Antimicrob Agents Chemother 52 (2008) 2442-2448
57. Liu M., Healy M.D., Dougherty B.A., Esposito K.M., Maurice T.C., Mazzucco C.E., Bruccoleri R.E., Davison D.B., Frosco M., Barrett J.F., and Wang Y.K. Conserved fungal genes as potential targets for broad-spectrum antifungal drug discovery. Eukaryot Cell 5 (2006) 638-649
58. Lupetti A., Brouwer C.P., Bogaards S.J., Welling M.M., De Heer E., Campa M., Van Dissel J.T., Frissen R.H., and Nibbering P.H. Human lactoferrin-derived peptide's antifungal activities against disseminated Candida albicans infection. J Infect Dis 196 (2007) 1416-1424
59. Maki K., Matsumoto S., Watabe E., Iguchi Y., Tomishima M., Ohki H., Yamada A., Ikeda F., Tawara S., and Mutoh S. Use of a serum-based antifungal susceptibility assay to predict the in vivo efficacy of novel echinocandin compounds. Microbiol Immunol 52 (2008) 383-391
60. Martin de la Escalera C., Aller A.I., Lopez-Oviedo E., Romero A., Martos A.I., Canton E., Peman J., Garcia Martos P., and Martin-Mazuelos E. Activity of BAL 4815 against filamentous fungi. Antimicrob Agents Chemother 61 (2008) 1083-1086
61. Martinez L.R., Bryan R.A., Apostolidis C., Morgenstern A., Casadevall A., and Dadachova E. Antibody-guided alpha radiation effectively damages fungal biofilms. Antimicrob Agents Chemother 50 (2006) 2132-2136
62. Marx F., Binder U., Leiter E., and Pocsi I. The Penecillium chrysogenum antifungal protein PAF, a promising tool for the development of new antifungal therapies and fungal cell biology studies. Cell Mol Life Sci 65 (2008) 445-454
63. Mattila P.E., Metz A.E., Rapaka R.R., Bauer L.D., and Steele C. Dectin-1 Fc targeting of Aspergillus fumigatus beta-glucans augments innate defense against invasive pulmonary aspergillosis. Antimicrob Agents Chemother 52 (2008) 1171-1172
64. McCarron P.A., Donnelly R.F., Marouf W., Calvert D.E., and Anti-adherent. antifungal activities of surfactant-coated poly (ethyleyanoacrylate) nanoparticles. Int J Pharm 340 (2007) 182-190
65. Melcer A., Lacka I., Gabriel I., Wojciechowski M., Liberek B., Wisniewski A., and Milewski S. Rational design of N-alkyl derivatives of 2-amino-2-deoxy-d-glucitol-6P as antifungal agents. Bioorg Med Chem Lett 17 (2007) 6602-6666
66. Messer S.A., Diekema D.J., Boyken L., Tendolkar S., Hollis R.J., and Pfaller M.A. Activities of micafungin against 315 invasive clinical isolates of fluconazole-resistant Candida spp. J Clin Microbiol 44 (2006) 324-326
67. Meyer V. A small protein that fights fungi: AFP as a new promising antifungal agent of biotechnological value. Appl Microbiol Biotechnol 78 (2008) 17-28
68. Mitsuyama J., Nomura N., Hasimoto K., Yamada E., Nishikawa H., Kaeriyama M., Kimura A., Todo Y., and Narita H. In vitro and in vivo antifungal activities of T-2307, a novel arylamidine. Antimicrob Agents Chemother 52 (2008) 1318-1324
69. Munoz A., Lopez-Garcia B., and Marcos J.F. Studies on the mode of action of the antifungal hexapeptide PAF26. Antimicrob Agents Chemother 50 (2006) 3847-3855
70. Nakamata K., Kurita T., Bhuiyan M.S.A., Sato K., Noda Y., and Yoda K. KEGI/YFR042w encodes a novel Kre6-binding endoplasmic reticulum membrane protein responsible for β-1,6-glucan synthesis in Saccharomyces cerevisiae. J Biol Chem 282 (2007) 34315-34324
71. Nazi I., Scott A., Sham A., Rossi L., Williamson P.R., Kronstad J.W., and Wright G.D. Role of homoserine transacetylase as a new target for antifungal agents. Antimicrob Agents Chemother 51 (2007) 1731-1736
72. Ng C.K., Obando D., Widmer F., Wright L.C., Sorrell T.C., and Jollife K.A. Correlation of antifungal activity with fungal phospholipase inhibition using a series of bisquaternary ammonium salts. J Med Chem 49 (2006) 811-816
73. Ngai P.H., and Ng T.B. A lectin with antifungal and mitogenic activities from red cluster pepper (Capsicum frutescens) seeds. Appl Microbiol Biotechnol 74 (2007) 366-371
74. Okumura Y., Ogawa K., Uchiya K., Komori Y., Nonogaki T., and Nikai T. Biological properties of elastase inhibitor, AFLEI from Aspergillus flavus. Nippon Ishinkin Gakkai Zasshi 49 (2008) 87-93
75. Omaetxebarria M.J., Moragues M.D., Elguezabal N., Rodriguez-Alejandra A., Brena S., Schneider J., Polonelli L., and Ponton J. Antifungal and antitumor activities of a monoclonal antibody directed against a stress mannoprotein of Candida albicans. Curr Mol Med 5 (2005) 393-401
76. Ota Y., Tatsuno K., Okugawa S., Yanagimoto S., Kitasawa T., Fukushima A., Tsukada K., and Koike K. Relationship between the initial dose of micafungin and its efficacy in patients with candidemia. J Infect Chemother 13 (2007) 208-212
77. Pachl J., Svoboda P., Jacobs F., Vandewoude K., Van der Hoven B., Spronk P., Masterson G., Malbrain M., Aoun M., Garbino J., Takala J., Drgona L., Burnie J., Matthews R., and For the Mycograb Invasive Candidiasis Study Group. A randomized, blinded, multicenter trial of lipid-associated amphotericin B alone versus in combination with an antibody-based inhibitor of heat shock protein 90 in patients with invasive candidiasis. Clin Infect Dis 42 (2006) 1404-1413
78. Paderu P., Garcia-Effron G., Balashov S., Delmas G., Park S., and Perlin D.S. Serum differentially alters the antifungal properties of echinocandin drugs. Antimicrob Agents Chemother 51 (2007) 2253-2256
79. Pai M.P., Samples M.L., Mercier R.C., and Spilde M.N. Activities and ultrastructural effects of antifungal combinations against simulated Candida endocardial vegetations. Antimicrob Agents Chemother 52 (2008) 2367-2376
80. Pascual A., Calandra T., Bolay S., Buclin T., Bille J., and Marchetti O. Voriconazole therapeutic drug monitoring in patients with invasive mycoses improves efficacy and safety outcomes. Clin Infect Dis 46 (2008) 201-211
81. Parish C.A., Smith S.K., Calati K., Zink D., Wilson K., Roemer T., Jiang B., Xu D., Bills G., Platas G., Peláez F., Díez M.T., Tsou N., McKeown A.E., Ball R.G., Powles M.A., Yeung L., Liberator P., and Harris G. Isolation and structure elucidation of parnafungins, antifungal natural products that inhibit mRNA polyadenylation. J Am Chem Soc 130 (2008) 7060-7066
82. Perkhofer S, Lechner V, Lass-Florl C. The in vitro activity of isavuconazole against Aspergillus species and zygomycetes according to EUCAST methodology. Antimicrob Agents Chemother. 2009. [In press].
83. Perlin D.S. Resistance to echinocandin-class antifungal drugs. Drug Resist Updates 10 (2007) 121-130
84. Petraitiene R., Petraitis V., Kelaher A.M., Sarafandi A.A., Mickiene D., Groll A.H., Sein T., Bacher J., and Walsh T.J. Efficacy, plasma pharmacokinetics, and safety of icofungipen, an inhibitor of Candida isoleucyl-tRNA synthetase, in treatment of experimental disseminated candidiasis in persistently neutropenic rabbits. Antimicrob Agents Chemother 49 (2005) 2084-2092
85. Pfaller M.A., Boyken L., Hollis R.J., Kroeger J., Messer S.A., Tendolkar S., and Diekema D.J. In vitro susceptibility of invasive isolates of Candida spp. to anidulafungin, caspofungin, and micafungin: six years of global surveillance. J Clin Microbiol 46 (2008) 150-156
86. Pfaller M.A., and Diekema D.J. Epidemiology of invasive candidiasis: a persistent public health problem. Clin Microbiol Rev 20 (2007) 133-163
87. Rauch I., Lundstrom L., Hell M., Sperl W., and Kofler B. Galanin message-associated peptide suppresses growth and the budded-to-hyphal-form transition of Candida albicans. Antimicrob Agents Chemother 51 (2007) 4167-4170
88. Rodriguez-Suarez R., Xu D., Veillette K., Davison J., Sillaots S., Kauffman S., Hu W., Bowman J., Martel N., Trosok S., Wang H., Zhang L., Huang L.Y., Li Y., Rahkhoodaee F., Ransom T., Gauvin D., Douglas C., Youngman P., Becker J., Jiang B., and Roemer T. Mechanism-of-action determination of GMP synthase inhibitors and target validation in Candida albicans and Aspergillus fumigatus. Chem Biol 14 (2007) 1163-1175
89. Rukayadi Y., and Hwang J.K. In vitro antimycotic activity of xanthorrhizol isolated from Curcuma xanthorrhiza Roxb. against opportunistic filamentous fungi. Phytother Res 21 (2007) 434-438
90. Saville S.P., Lazzell A.L., Bryant A.P., Fretzen A., Monreal A., Solberg E.O., Monteagudo C., Lopez-Ribot J.L., and Milne G.T. Inhibition of filamentation can be used to treat disseminated candidiasis. Antimicrob Agents Chemother 50 (2006) 3312-3316
91. Segal B.H., and Walsh T.J. Current approaches to diagnosis and treatment of invasive aspergillosis. Am J Respir Crit Care Med 173 (2006) 707-717
92. Seifert H., Aurbach U., Stefanik D., and Cornely O. In vitro activities of isavuconazole and other antifungal agents against Candida bloodstream isolates. Antimicrob Agents Chemother 51 (2007) 1818-1821
93. Serena C., Fernandez-Torres B., Pastor F.J., Trilles L., Dos Santos Lazera M., Nolard N., and Guarro J. In vitro interactions of micafungin with other antifungal drugs against clinical isolates of four species of Cryptococcus. Antimicrob Agents Chemother 49 (2005) 2994-2996
94. Shubitz L.F., Galgiani J.N., Tian Z.Q., Zhong Z., Timmermans P., and Katz L. Efficacy of ambruticin analogs in a murine model of coccidioidomycosis. Antimicrob Agents Chemother 50 (2006) 3467-3469
95. Simon A., Kullberg B.J., Tripet B., Boerman O.C., Zeeuwen P., Van der Ven-Jongekrijg J., Verweij P., Schalkwijk J., Hodges R., van der Meer J.W.M., and Netea M.G. Drosomycin-like defensin, a human homologue of Drosophila melanogaster drosomycin with antifungal activity. Antimicrob Agents Chemother 52 (2008) 1407-1412
96. Smith J., Safdar N., Knasinski V., Simmons W., Bhavnani S.M., Ambrose P.G., and Andes D. Voriconazole therapeutic drug monitoring. Antimicrob Agents Chemother 50 (2006) 1570-1572
97. Steinbach W.J., Cramer Jr. R.A., Perfect B.Z., Henn C., Nielsen K., Heitman J., and Perfect J.R. Calcineurin inhibition or mutation enhances cell wall inhibitors against Aspergillus fumigatus. Antimicrob Agents Chemother 51 (2007) 2979-2981
98. Sun L, Sun S, Cheng A, Wu X, Zhang Y, Lou H. In vitro activities of retigeric acid B alone and in combination with azole antifungal agents against Candida albicans. Antimicrob Agents Chemother. 2009.[ In press].
99. Sung W.S., and Lee D.G. The candidacidal activity of indole-3-carbinol that binds with DNA. IUBMB Life 59 (2007) 408-412
100. Sung W.S., Lee J., and Lee D.G. Fungicidal effect and the mode of action of piscidin 2 derived from hybrid striped bass. Biochem Biophys Res Commun 371 (2008) 551-555
101. Tavares P.M., Thevissen K., Cammue B.P.A., Francois I.E.J.A., Barreto-Bergter E., Taborda C.P., Marques A.F., Rodrigues M.L., and Nimrichter L. In vitro activity of the antifungal plant defensin RsAFP2 against Candida isolates and its in vivo efficacy in prophylactic murine models of candidiasis. Antimicrob Agents Chemother 52 (2008) 4522-4525
102. Thati B., Noble A., Rowan R., Creaven B.S., Walsh M., McCann M., Egan D., and Kavanagh K. Mechanism of action of coumarin and silver(l)-coumarin complexes against the pathogenic yeast Candida albicans. Toxicol In Vitro 21 (2007) 801-808
103. Tomishima M., Ohki H., Yamada A., Maki K., and Ikeda F. Novel echinocandin antifungals. Part 2: optimization of the side chain of the natural product FR901379. Discovery of micafungin. Bioorg Med Chem Lett 18 (2008) 2886-2890
104. Vallon-Eberhard A., Makovitzki A., Beauvais A., Latge J.P., Jung S., and Shai Y. Efficient clearance of Aspergillus fumigatus in murine lungs by an ultrashort antimicrobial lipopeptide, palmitoyl-lys-ala-Dala-lys. Antimicrob Agents Chemother 52 (2008) 3118-3126
105. Viera D.B., and Carmona-Ribeiro R.M. Cationic lipids and surfactants as antifungal agents: mode of action. J Antimicrob Chemother 58 (2006) 760-767
106. Wakiec W., Gabriel I., Prasad R., Becker J.M., Payne J.W., and Milewski S. Enhanced susceptibility to antifungal oligopeptides in yeast strains overexpressing ABC multidrug efflux pumps. Antimicrob Agents Chemother (2008) 4057-4063
107. Widmer F., Wright L.C., Obando D., Handke R., Ganendren R., Ellis D.H., Sorrell T.C., and Hexadecylphosphocholine. (miltefosine) has broad-spectrum fungicidal activity and is efficacious in a mouse model of cryptococcosis. Antimicrob Agents Chemother 50 (2006) 414-421
108. Xu D., Jiang B., Ketela T., Lemieux S., Veillette K., Martel N., Davison J., Sillaots S., Trosok S., Bachewich C., Bussey H., Youngman P., and Roemer T. Genome-wide fitness test and mechanism-of-action studies of inhibitory compounds in Candida albicans. PloS Pathog 3 (2007) e92
109. Yano T., Aoyagi A., Kozuma S., Kawamura Y., Tanaka I., Suzuki Y., Takamatsu Y., Takatsu T., and Inukai M. Pleofungins, novel inositol phosphorylceramide synthase inhibitors, from Phoma sp. SANK 13899. Taxonomy, fermentation, isolation, and biological activities. J Antibiot (Tokyo) 60 (2007) 136-142
110. Yim N.H., Hwang E.I., Yun B.S., Park K.D., Moon J.S., Lee S.H., Sung N.D., and Kim S.U. Sesquiterpene furan compound C-J-01, a novel chitin synthase 2 inhibitor from Chloranthus japonicus SIEB. Biol Pharm Bull 31 (2008) 1041-1044
111. Yordanov M., Dimitrova P., Patkar S., Saso L., and Ivanovska N. Inhibition of Candida albicans extracellular enzyme activity by selected natural substances and their application in Candida infection. Can J Microbiol 54 (2008) 435-440
112. Yu F., Zaleta-Rivera K., Zhu X., Huffman J., Millet J.C., Harris S.D., Yuen G., Li X.C., and Du L. Structure and biosynthesis of heat-stable antifungal factor (HSAF), a broad-spectrum antimycotic with a novel mode of action. Antimicrob Agents Chemother 51 (2007) 64-72
113. Zaas A.K. In the modern day, what are the potential advantages of echinocandins over azoles and polyenes in drug interactions?. J Invasive Fungal Infect 1 (2007) 133-142
114. Zhu J., Luther P.W., Leng Q., and Mixson A.J. Synthetic histidine-rich peptides inhibit Candida species and other fungi in vitro: role of endocytosis and treatment implications. Antimicrob Agents Chemother 50 (2006) 2797-2805